Reduction in drug-induced DNA double-strand breaks associated with β1 integrin-mediated adhesion correlates with drug resistance in U937 cells

Blood

Volumn 98, Issue 6, 2001, Pages 1897-1903

  Hazlehurst, Lori A ^a   Valkov, Nikola ^a   Wisner, Lee ^a   Storey, Jonathan A ^a   Boulware, David ^a   Sullivan, Daniel M ^a   Dalton, William S ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1 INTEGRIN; DOUBLE STRANDED DNA; DOXORUBICIN; ETOPOSIDE; GYRASE INHIBITOR; MITOXANTRONE;

APOPTOSIS; ARTICLE; CELL ADHESION; CELL LINE; CELL SURVIVAL; CELLULAR DISTRIBUTION; COMET ASSAY; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA BINDING; DNA DAMAGE; DNA STRAND BREAKAGE; DRUG RESISTANCE; HUMAN; HUMAN CELL; LYMPHOMA CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONTENT;

EID: 0035885933     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.6.1897     Document Type: Article

References (33)

1. Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood. 1999;93:1658-1667.
2. Sethi T, Rintoul RC, Moore SM, et al. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat Med. 1999;5:662-668.
3. Drake FH, Hofman GA, Bartus HF, Mattern MR, Crooke ST, Mirabelli CK. Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II. Biochemistry. 1989;28:8154-8160.
4. Turley H, Comley M, Houlbrook S, et al. The distribution and expression of the two isoforms of DNA topoisomerase II in normal and neoplastic human tissues. Br J Cancer. 1997;75:1340-1346.
5. Tewey KM, Rowe TC, Yang L, Halligan BD, Liu LF. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science. 1984;226:466-468.
6. Ganapathi R, Constantinou A, Kamath N, Dubyak G, Grabowski D, Krivacic K. Resistance to etoposide in human leukemia HL-60 cells: reduction in drug-induced DNA cleavage associated with hypophosphorylation of topoisomerase II phosphopeptides. Mol Pharmacol. 1996;50:243-248.
7. Sullivan DM, Glisson BS, Hodges PK, Smallwood-Kentro S, Ross WE. Proliferation dependence of topoisomerase II mediated drug action. Biochemistry. 1986;25:2248-2256.
8. Scheltema JM, Romijn JC, van Steenbrugge GJ, Beck WT, Schroder FH, Mickisch GH. Decreased levels of topoisomerase II α in human renal cell carcinoma lines resistant to etoposide. J Cancer Res Clin Oncol. 1997;123:546-554.
9. Kohn KW. Principles and practice of DNA filter elution. Pharmacol Ther. 1991;49:55-77.
10. Valkov NI, Gump JL, Engel R, Sullivan DM. Cell density-dependent VP-16 sensitivity of leukaemic cells is accompanied by the translocation of topoisomerase IIα from the nucleus to the cytoplasm. Br J Haematol. 2000;108:331-345.
11. Beidler DR, Cheng YC. Camptothecin induction of a time- and concentration-dependent decrease of topoisomerase I and its application in camptothecin activity. Mol Pharmacol. 1995;47:907-914.
12. Kent CR, Eady JJ, Ross GM, Steel GG. The comet moment as a measure of DNA damage in the comet assay. Int J Radiat Biol. 1995;67:655-660.
13. Smith PJ, Morgan SA, Fox ME, Watson JV. Ml-toxantrone-DNA binding and the induction of topoisomerase II associated DNA damage in multidrug resistant small cell lung cancer cells. Biochem Pharmacol. 1990;40:2069-2078.
14. Hazlehurst LA, Krapcho AP, Hacker MP. Comparison of aza-anthracenedione-induced DNA damage and cytotoxicity in experimental tumor cells. Biochem Pharmacol. 1995;50:1087-1094.
15. Woynarowski JM, Sigmund RD, Beerman TA. Topoisomerase-II-mediated lesions in nascent DNA: comparison of the effects of epipodophyllotoxin derivatives, VM-26 and VP-16, and 9-anilinoacridine derivatives, m-AMSA and o-AMSA. Biochim Biophys Acta. 1988;950:21-29.
16. Harker WG, Slade DL, Drake FH, Parr RL. Mitoxantrone resistance in HL-60 leukemia cells: reduced nuclear topoisomerase II catalytic activity and drug-induced DNA cleavage in association with reduced expression of the topoisomerase β isoform. Biochemistry. 1991;30:9953-9961.
17. Hazlehurst LA, Foley NE, Gleason-Guzman MC, et al. Multiple mechanisms confer drug-resistance to mitoxantrone in the human 8226 myeloma cell line. Cancer Res. 1999;59:1021-1028.
18. Durand RE, Sutherland RM. Effects of intercellular contact on repair of radiation damage. Exp Cell Res. 1972;71:75-80.
19. Luo C, Johnston PJ, MacPhail SH, Banath JP, Olive PL. Cell fusion studies to examine the mechanism for etoposide resistance in Chinese hamster V79 spheroids. Exp Cell Res. 1998;243:282-289.
20. Oloumi A, MacPhail SH, Johnston PJ, Banath JP, Olive PL. Changes in subcellular distribution of topoisomerase IIα correlate with etoposide resistance in multicell spheroids and xenograft tumors. Cancer Res. 2000;60:5747-5753.
21. Hoyt DG, Rusnak JM, Mannix RJ, Modzelewski RA, Johnson CS, Lazo JS. Integrin activation suppresses etoposide-induced DNA strand breakage in cultured murine tumor-derived endothelial cells. Cancer Res. 1996;56:4146-4149.
22. Hazlehurst LA, Damiano JS, Buyuksal I, Pledger WJ, Dalton WS. Adhesion to fibronectin via β1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR). Oncogene. 2000;38:4319-4327.
23. Isaacs RJ, Davies SL, Sandru MI, Redwood C, Wells NJ, Hickson ID. Physiological regulation of eukaryotic topoisomerase II. Biochim Biophys Acta. 1998;1400:121-137.
24. Darby MK, Schmitt B, Jongstra-Bilen J, Vosberg H-P. Inhibition of calf thymus type II DNA topoisomerase by poly(ADP-ribosylation). EMBO J. 1985;4:2129-2134.
25. Tsai SC, Valkov N, Yang WM, Gump J, Sullivan D, Seto E. Histone deacetylase interacts directly with DNA topoisomerase II. Nat Genet. 2000;26:349-353.
26. Tong JK, Hassig CA, Schnitzler GR, Kingston RE, Schreiber SL. Chromatin deacetylation by an ATP-dependent nucleosome remodelling complex. Nature. 1998;395:917-921.
27. Zhang Y, LeRoy G, Seelig HP, Lane WS, Reinberg D. The dermatomyositis-specific autoantigen Mi2 is a component of a complex containing histone deacetylase and nucleosome remodeling activities. Cell. 1998;95:279-289.
28. Errington F, Wiltmore E, Tilby MJ, et al. Murine transgenic cells lacking DNA topoisomerase IIβ are resistant to acridines and mitoxantrone: analysis of cytotoxicity and cleavable complex formation. Mol Pharmacol. 1999;56:1309-1316.
29. Meng F, Lowell CA. A β 1 integrin signaling pathway involving Src-family kinases, Cbl and PI-3 kinase is required for macrophage spreading and migration. EMBO J. 1998;17:4391-4403.
30. Lee JW, Juliano RL. α5 β1 Integrin protects intestinal epithelial cells from apoptosis through a phosphatidylinositol 3-kinase and protein kinase B-dependent pathway. Mol Biol Cell. 2000;11:1973-1987.
31. King WG, Mattaliano MD, Chan TO, Tsichilis PN, Brugge JS. Phosphatidylinositol 3-kinase is required for integrin-stimulated AKT and RAF-1/mitogen-activated protein kinase pathway activation. Mol Cell Biol. 1997;17:4406-4418.
32. Lin TH, Aplin AE, Shen Y, et al. Integrin-mediated activation of MAP kinase is independent of FAK: evidence for dual integrin signaling pathways in fibroblasts. J Cell Biol. 1997;136:1385-1395.
33. Hanks SK, Calalb MB, Harper MC, Patel SK. Focal adhesion protein-tyrosine kinase phosphorylated in response to cell attachment to fibronectin. Proc Natl Acad Sci U S A. 1992;89:8487-8491.